Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Annexon, Inc. secures a strategic credit facility of up to $200 million from Oxford Finance to strengthen its financial capabilities for global commercialization.

PUBLIC · ANNXJul 30, 2026•10 days ago

Amount Raised

$50 Million

Round Type

Debt Financing

South San FranciscoBiotechnology

Investors

Oxford Finance Llc

Description

Annexon, Inc. has entered into a strategic credit facility agreement with Oxford Finance for up to $200 million. The initial draw of $50 million will support the company's growth strategy for its neuroinflammatory disease treatments. The facility is designed to diversify Annexon's capital structure with non-dilutive funding

Company Information

Company

Annexon

Location

180 Kimball Way Suite 200

South San Francisco, California, United States

About

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

Related People

Suggested for you
1 contact
Verified contactsMichael O., Executive Officer
Predictive Intelligence
Strategic

ML-powered predictions for Annexon's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.